TITLE

PHARMAGENESIS JOINT VENTURE TO MAKE/SELL PG2 IN CHINA

PUB. DATE
July 2001
SOURCE
Worldwide Biotech;Jul2001, Vol. 13 Issue 7, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Deals with the joint venture forged by Pharmagenesis Inc. in Palo Alto, California, with Tianjin Zhong Xin Pharmaceutical Group company in China to manufacture and market the cancer therapy drug PG2 developed by Pharmagenesis in China.
ACCESSION #
4764380

 

Related Articles

  • PHARMAGENESIS APPROVED TO SELL FERIDEX IN CHINA.  // Worldwide Biotech;Apr2001, Vol. 13 Issue 4, p1 

    Reports on the approval received by Pharmagenesis Inc. from the Chinese State Drug Administration to market and sell Feridex, a magnetic resonance imaging contrast agent designed for the early detection of liver lesions, in China.

  • CHINA CERTIFIES PHARMAGENESIS' BONE MARROW STIMULANT PG2.  // Worldwide Biotech;Nov2001, Vol. 13 Issue 11, p1 

    Reports on a drug certificate awarded by China's State Drug Administration to Pharmagenesis Inc. for its plant-derived hematopoiesis enhancer PG2.

  • Eli Lilly and Pharmagenesis agree to research antifungals from plants.  // Chemical Market Reporter;11/11/96, Vol. 250 Issue 20, p19 

    Reports on the collaboration of Pharmagenesis Inc. and Eli Lilly and Co. to isolate and develop antifungal agents derived from microorganisms associated with plants known to be resistant to fungal infections.

  • PIERRE FABRE LICENSES PHARMAGENESIS ANTI-CANCER HERBAL DRUG.  // Worldwide Biotech;May2003, Vol. 15 Issue 5, p5 

    Reports that research and development company, Pharmagenesis Inc. has signed an agreement with Pierre Fabre Medicament to license PG490-88Na, a patented derivative of a compound from a plant widely used in Chinese medicine.

  • From Europe to China--a new focus. Wechsler, Jill // Pharmaceutical Executive;Sep97, Vol. 17 Issue 9, p20 

    Focuses on the pharmaceutical industry in the People's Republic of China. Signing of the Mutual Recognition Agreement on pharmaceutical plant inspection between the United States and Europe; Upgrading of domestic pharmaceutical capabilities in the country; Difficulty of drug distribution in the...

  • Ethics & enterprise--industry's dilemma. Schwartz, Harry // Pharmaceutical Executive;Nov97, Vol. 17 Issue 11, p24 

    Discusses the problems faced by the pharmaceutical industry in the United States involving ethical issues and standard practices. Collapse in the diet-drug demand due to its alleged adverse reaction; Lawsuit faced by SmithKline Beecham; Pediatric drugs not properly labeled and tested; Stiff...

  • Nigeria--strategy & strength for industry. Akanmu, Olu // Pharmaceutical Executive;Nov97, Vol. 17 Issue 11, p74 

    Focuses on the status and the restructuring trend of the pharmaceutical industry in Nigeria. Glaxo Wellcome's restructured business; Economic conditions of Nigeria; Government policies toward business; Presence of diverse pharmaceutical companies; Sale of over-the-counter drugs; Logistics and...

  • Information showcase.  // Pharmaceutical Executive;Nov97, Vol. 17 Issue 11, p85 

    Showcases products and services related to the pharmaceutical industry in the United States. Includes marketing support services; Book entitled `Contemporary Pharmacoeconomics'; Medical handbooks; Reporting services; Production services; Biotechnology support.

  • Homeopathic drugs naturally want spot in mainstream market. Magiera, Marcy; Colford, Steven W. // Advertising Age;8/31/92, Vol. 63 Issue 35, p3 

    Reports that marketers of homeopathic medicines want to write a prescription for the American mainstream and they are spending marketing dollars doing it. Remedies that treat an ailment with small doses of natural substances; Commonly available in Europe; Homeopathic marketers expect that to...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics